Tags : ITI-1284

Pharma

Intra-Cellular Reports the Expansion of Pipeline with the Addition of

Shots: Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the […]Read More